

Supporting Information

Enantioselective Difunctionalization of Alkenes by a Palladium-Catalyzed Heck/Borylation Sequence

Yuanqi Wu,^a Lizuo Wu,^a Zhanming Zhang*,^b Bing Xu,^b Yu Liu*,^a Junliang Zhang*^b

^aJilin Provincial Key Laboratory of Carbon Fiber Development and Application, College of Chemistry and Life Science, Advanced Institute of Materials Science, Changchun University of Technology, Changchun 130012, P.R. China;

^bDepartment of Chemistry, Fudan University, 2005 Songhu Road, Shanghai, 200438, P.R. China


Contents

1. General Information.....	2
2. Table S1. Screening of the ligands	2
3. Table S2. Screening of the Amount of H ₂ O for Heck/Borylation Sequence.....	3
4. Typical procedure for Palladium-Catalyzed Enantioselective Heck/Borylation Sequence...3	
5. Synthetic Transformations	21
6. X-ray structure of 4d	23
7. ¹ H, ¹⁹ F, ¹³ C NMR and HPLC Spectra	23
8. References.....	110

1. General Information


All reactions were carried out under an atmosphere of nitrogen in flame-dried glassware with magnetic stirring. ^1H NMR spectra, ^{19}F NMR spectra, ^{13}C NMR spectra were recorded on a Bruker 300, 400 and 500 MHz spectrometer in CDCl_3 or acetone- d_6 . All signals are reported in ppm with the internal TMS signal at 0 ppm as a standard. Data for ^1H NMR spectra are reported as follows: chemical shift (ppm, referenced to TMS; s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = doublet of triplets, m = multiplet), coupling constant (Hz), and integration. Data for ^{13}C NMR are reported in terms of chemical shift (ppm) relative to residual solvent peak (CDCl_3 : 77.0 ppm). Reactions were monitored by thin layer chromatography (TLC) using silica gel plates. Flash column chromatography was performed over silica gel (300-400 mesh). The ligands (*R, Rs*)-*N*-Me-PC1,^[1] Wei-Phos,^[2] (*S, Rs*)-**X1**, (*S, Rs*)-*N*-Me-**X1**,^[3] (*R, Rs*)-**M1**, (*R, Rs*)-*N*-Me-**M1**, (*S, Rs*)-**M1**, (*S, Rs*)-*N*-Me-**M1**,^[4] (*R, Rs*)-**Xu1**, (*R, Rs*)-*N*-Me-**Xu1**, (*S, Rs*)-**Xu1**, (*S, Rs*)-*N*-Me-**Xu1**, (*S, Rs*)-*N*-Me-**Xu3**^[5] and substrates **1a-1aa**, **3a-3g**, **3i**, **3j**^[6], **3h**^[7], **3k**^[8], were synthesized according to published procedures. The spectral data of the substrates were consistent with that reported in the literature. The enantiomeric excesses of the products were determined by chiral stationary phase HPLC using a Chiralpak AD-3, IC, AD-H, OJH.

2. Table S1. Screening of the ligands



^aReaction conditions: **1a** (0.1 mmol), B₂Pin₂ (1.1 equiv.), Pd₂(dba)₃·CHCl₃ (5 mol%), Ligand (20 mol%), Cs₂CO₃ (2.0 equiv.), 1 mL of solvent under N₂ atmosphere at 100 °C for 12 h. ^bDetermined by ^1H NMR analysis with CH₂Br₂ as an internal standard. ^cThe ee value of **2a** was determined by HPLC analysis.

3. Table S2. Screening of the Amount of H₂O for Heck/Borylation Sequence




Entry	H ₂ O (x)	Yield (%) ^b	ee (%) ^c
1	1.0	97	88
2	2.0	98	89
3	3.0	97	90
4	4.0	97	91
5	5.0	95	91
6	6.0	96	90

^aReaction conditions: **1a** (0.1 mmol), B₂Pin₂ (1.1 equiv), Pd₂(dba)₃·CHCl₃ (2.5 mol%), *N*-Me-Xu3 (10 mol%), Cs₂CO₃ (2.0 equiv), 1 mL of Et₂O under N₂ atmosphere at 100 °C for 12h. ^bDetermined by ¹H NMR analysis with CH₂Br₂ as the internal standard. ^cDetermined by HPLC analysis.

4. Typical procedure for Palladium-Catalyzed Enantioselective Heck/Borylation Sequence.

To a sealed tube was added Pd₂(dba)₃·CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%), B₂Pin₂ (0.33 mmol) and Cs₂CO₃ (0.6 mmol). The flask was evacuated and refilled with argon. Then *o*-iodophenol-derived allyl ether **1** (0.3 mmol), Et₂O (3 mL) and H₂O (22 μL) was added to the tube, and stirred at 80 °C. Following complete consumption of the allyl ether **1** (monitored by TLC), solvent was removed under reduced pressure. The crude product was then purified by flash column chromatography on silica gel to afford the desired product.


4.1 Synthesis of (*R*)-4,4,5,5-tetramethyl-2-((3-methyl-2,3-dihydrobenzofuran-3-yl)methyl)-1,3,2-dioxaborolane (**2a**).



Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃·CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1a** (82.2 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol),

Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2a** as a colorless ropy liquid (81 mg, 98% yield) with 91% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.14 (dd, *J* = 7.4, 1.4 Hz, 1H), 7.08 (td, *J* = 7.7, 1.5 Hz, 1H), 6.84 (td, *J* = 7.4, 1.0 Hz, 1H), 6.79-6.72 (m, 1H), 4.41 (d, *J* = 8.6 Hz, 1H), 4.25 (d, *J* = 8.6 Hz, 1H), 1.37 (s, 3H), 1.30 (d, *J* = 15.5 Hz, 1H), 1.24 (d, *J* = 13.7 Hz, 1H), 1.19 (s, 6H), 1.18 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 158.95, 137.29, 127.64, 122.54, 120.31, 109.40, 84.04, 83.13, 43.11, 28.04, 24.75, 24.69. MS (EI): *m/z* (%) = 275 (M+H⁺, 2.75), 133 (100); HRMS calculated for [C₁₆H₂₄BO₃]⁺: 275.1803 found: 275.1807. Enantiomeric excess was determined by HPLC with a Chiralpak AD-3 column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 9.8 min, major enantiomer *tr* = 10.3 min. [α]_D²⁵ = 20.6 (c = 0.4, CHCl₃).


4.2 Synthesis of (*S*)-2-((3-ethyl-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**2b**).



2b

Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1b** (86.5 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2b** as a colorless ropy liquid (60.5 mg, 70% yield) with 92% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.07-6.96 (m, 2H), 6.79-6.73 (m, 1H), 6.66 (d, *J* = 8.0 Hz, 1H), 4.38-4.25 (m, 2H), 1.70-1.53 (m, 2H), 1.24 (d, *J* = 15.4 Hz, 1H), 1.13 (d, *J* = 15.4 Hz, 1H), 1.08 (s, 6H), 1.05 (s, 6H), 0.72 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 159.70, 135.07, 127.70, 123.33, 120.04, 109.17, 83.08, 81.81, 46.90, 34.09, 24.69, 24.63, 8.89. MS (EI): *m/z* (%) = 289 (M+H⁺, 7.85), 147 (100); HRMS calculated for [C₁₇H₂₆BO₃]⁺: 289.1970 found: 289.1964. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 9.5 min, major enantiomer *tr* = 13.0 min. [α]_D²⁵ = 25.4 (c = 0.4, CHCl₃).

4.3 Synthesis of (*S*)-4,4,5,5-tetramethyl-2-((3-propyl-2,3-dihydrobenzofuran-3-yl)methyl)-1,3,2-dioxaborolane (**2c**).




2c

Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1c** (90.6 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2c** as a colorless ropy liquid (73 mg, 81% yield) with 91% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.08-6.95 (m, 2H), 6.79-6.71 (m, 1H), 6.69-6.62 (m, 1H), 4.35-4.26 (m, 2H), 1.64-1.45 (m, 2H), 1.35-1.22 (m, 2H), 1.22-1.10 (m, 2H), 1.08 (s, 6H), 1.06 (s, 6H), 0.77 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 159.59, 135.50, 127.67, 123.30, 120.05, 109.19, 83.07, 82.26, 46.60, 44.10, 24.68, 24.63, 17.79, 14.49. MS (EI): *m/z* (%) = 303 (M+H⁺, 7.22), 83 (100); HRMS calculated for [C₁₈H₂₈BO₃]⁺: 303.2126 found: 303.2120.


Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer t_r = 9.1 min, major enantiomer t_r = 12.7 min. $[\alpha]_D^{25} = 27.7$ ($c = 0.4$, CHCl_3).

4.4 Synthesis of (*S*)-2-((3-butyl-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**2d**).




Prepared according to typical procedure at 80 °C for 12 h by using $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1d** (94.9 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μL , 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2d** as a colorless ropy liquid (76.6 mg, 81% yield) with 92% *ee*. ^1H NMR (400 MHz, CDCl_3) δ 7.08-6.96 (m, 2H), 6.80-6.72 (m, 1H), 6.69-6.63 (m, 1H), 4.35-4.27 (m, 2H), 1.67-1.47 (m, 2H), 1.25 (d, $J = 15.5$ Hz, 2H), 1.20-1.10 (m, 4H), 1.09 (s, 6H), 1.06 (s, 6H), 0.77 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 159.60, 135.58, 127.68, 123.33, 120.08, 109.23, 83.10, 82.28, 46.54, 41.38, 26.70, 24.70, 24.67, 23.13, 13.96. MS (EI): m/z (%) = 317 ($\text{M}+\text{H}^+$, 4.40), 83 (100); HRMS calculated for $[\text{C}_{19}\text{H}_{30}\text{BO}_3]^+$: 317.2283 found: 317.2275. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer t_r = 8.9 min, major enantiomer t_r = 12.3 min. $[\alpha]_D^{25} = 21.8$ ($c = 0.4$, CHCl_3).

4.5 Synthesis of (*S*)-2-((3-isopropyl-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**2e**).




Prepared according to typical procedure at 80 °C for 12 h by using $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1e** (90.7 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μL , 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2e** as a colorless ropy liquid (77.7 mg, 90% yield) with 93% *ee*. ^1H NMR (400 MHz, CDCl_3) δ 7.06-6.95 (m, 2H), 6.77-6.70 (m, 1H), 6.66-6.60 (m, 1H), 4.42-4.30 (m, 2H), 1.91-1.78 (m, 1H), 1.26 (d, $J = 15.2$ Hz, 1H), 1.14 (d, $J = 15.2$ Hz, 1H), 1.02 (s, 6H), 0.97 (s, 6H), 0.78 (d, $J = 6.8$ Hz, 3H), 0.72 (d, $J = 6.8$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 160.08, 133.84, 127.73, 124.05, 119.73, 108.96, 82.94, 79.73, 49.96, 37.15, 24.65, 24.43, 17.74, 17.57. MS (EI): m/z (%) = 303 ($\text{M}+\text{H}^+$, 3.19), 259 (100); HRMS calculated for $[\text{C}_{18}\text{H}_{27}\text{BO}_3]^+$: 303.2126 found: 303.2119. Enantiomeric excess was determined by HPLC with a Chiralpak AD-3 column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer t_r = 9.4 min, major enantiomer t_r = 10.1 min. $[\alpha]_D^{25} = 32.8$ ($c = 0.4$, CHCl_3).

4.6 Synthesis of (*S*)-2-((3-(tert-butyl)-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**2f**).




Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1f** (94.9 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2f** as a colorless ropy liquid (80.4 mg, 85% yield) with 92% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.08-7.02 (m, 1H), 7.02-6.95 (m, 1H), 6.75-6.67 (m, 1H), 6.64-6.58 (m, 1H), 4.55-4.45 (m, 2H), 1.39 (d, *J* = 14.9 Hz, 1H), 1.02 (d, *J* = 14.7 Hz, 1H), 0.93 (s, 6H), 0.82 (s, 15H). ¹³C NMR (101 MHz, CDCl₃) δ 160.56, 132.61, 127.78, 125.75, 119.19, 108.83, 82.80, 78.75, 52.43, 37.02, 25.22, 24.64, 24.17. MS (EI): *m/z* (%) = 317 (M+H⁺, 0.97), 83 (100); HRMS calculated for [C₁₉H₃₀BO₃]⁺: 317.2283 found: 317.2276. Enantiomeric excess was determined by HPLC with a Chiralpak AD-3 column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 10.5 min, major enantiomer *tr* = 8.5 min. [α]_D²⁵ = 41.5 (c = 0.4, CHCl₃).

4.7 Synthesis of (*S*)-2-((3-benzyl-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**2g**).




Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1g** (105.1 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2g** as a colorless ropy liquid (81.8 mg, 78% yield) with 92% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.14-7.07 (m, 3H), 7.05-6.95 (m, 1H), 6.88-6.76 (m, 3H), 6.71 (t, *J* = 7.4 Hz, 1H), 6.62 (d, *J* = 8.0 Hz, 1H), 4.44 (d, *J* = 8.8 Hz, 1H), 4.26 (d, *J* = 8.8 Hz, 1H), 2.86 (s, 2H), 1.26 (d, *J* = 15.6 Hz, 1H), 1.15 (d, *J* = 15.6 Hz, 1H), 1.09 (s, 6H), 1.06 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.58, 137.65, 134.64, 130.50, 127.94, 127.68, 126.24, 124.05, 119.80, 109.32, 83.17, 81.72, 47.51, 46.96, 24.72, 24.64. MS (EI): *m/z* (%) = 350 (M⁺, 1.84), 259 (100); HRMS calculated for [C₂₂H₂₇BO₃Na]⁺: 373.1945 found: 373.1938. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 12.1 min, major enantiomer *tr* = 16.1 min. [α]_D²⁵ = 27.5 (c = 0.4, CHCl₃).

4.8 Synthesis of (*S*)-4,4,5,5-tetramethyl-2-((3-(4-methylbenzyl)-2,3-dihydrobenzofuran-3-yl)methyl)-1,3,2-dioxaborolane (**2h**).




Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1h** (109.2 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2h** as a colorless ropy liquid (91.8 mg, 84% yield) with 94% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.11-7.03 (m, 1H), 6.99 (d, *J* = 7.7 Hz, 2H), 6.93-6.87 (m, 1H), 6.85-6.74 (m, 3H), 6.69 (d, *J* = 7.9 Hz, 1H), 4.51 (d, *J* = 8.8 Hz, 1H), 4.33 (d, *J* = 8.8 Hz, 1H), 2.90 (s, 2H), 2.28 (s, 3H), 1.32 (d, *J* = 15.7 Hz, 1H), 1.22 (d, *J* = 15.6 Hz, 1H), 1.15 (s, 6H), 1.13 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.60, 135.65, 134.79, 134.54, 130.36, 128.41, 127.87, 124.05, 119.78, 109.28, 83.12, 81.69, 47.49, 46.56, 24.71, 24.62, 20.96. MS (EI): *m/z* (%) = 365 (M+H⁺, 0.33), 259 (100); HRMS calculated for [C₂₃H₃₀BO₃]⁺: 365.2283 found: 365.2275. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 13.1 min, major enantiomer *tr* = 16.7 min. [α]_D²⁵ = 32.6 (*c* = 0.4, CHCl₃).

4.9 Synthesis of (*S*)-2-((3-(4-fluorobenzyl)-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**2i**).



Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1i** (110.5 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2i** as a colorless ropy liquid (101.2 mg, 92% yield) with 93% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.11-7.04 (m, 1H), 6.92-6.76 (m, 6H), 6.69 (d, *J* = 8.0 Hz, 1H), 4.48 (d, *J* = 8.9 Hz, 1H), 4.33 (d, *J* = 8.9 Hz, 1H), 2.90 (s, 2H), 1.34 (d, *J* = 15.6 Hz, 1H), 1.22 (d, *J* = 15.6 Hz, 1H), 1.18 (s, 6H), 1.15 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 161.65 (d, *J* = 244.3 Hz), 159.60, 134.31, 133.33 (d, *J* = 3.3 Hz), 131.81 (d, *J* = 7.8 Hz), 128.07, 123.99, 119.86, 114.45 (d, *J* = 21.0 Hz), 109.40, 83.27, 81.66, 47.51, 46.11, 24.74, 24.67. ¹⁹F NMR (376 MHz, CDCl₃) δ -116.91. MS (EI): *m/z* (%) = 369 (M+H⁺, 0.28), 259 (100); HRMS calculated for [C₂₂H₂₇BFO₃]⁺: 369.2032 found: 369.2015. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 11.0 min, major enantiomer *tr* = 17.6 min. [α]_D²⁵ = 27.4 (*c* = 0.4, CHCl₃).


4.10 Synthesis of (*S*)-2-((3-(4-chlorobenzyl)-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**2j**).



Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1j** (115.4 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol),


Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2j** as a colorless ropy liquid (110.2 mg, 95% yield) with 93% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.18-7.11 (m, 2H), 7.10-7.05 (m, 1H), 6.88-6.75 (m, 4H), 6.69 (d, *J* = 8.0 Hz, 1H), 4.47 (d, *J* = 8.9 Hz, 1H), 4.33 (d, *J* = 8.9 Hz, 1H), 2.89 (s, 2H), 1.30 (d, *J* = 9.7 Hz, 1H), 1.24 (d, *J* = 7.8 Hz, 1H), 1.17 (s, 6H), 1.15 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.55, 136.09, 134.17, 132.18, 131.72, 128.10, 127.77, 123.94, 119.87, 109.43, 83.25, 81.61, 47.44, 46.23, 24.72, 24.63. MS (EI): *m/z* (%) = 384 (M⁺, 0.56), 259 (100); HRMS calculated for [C₂₂H₂₇BClO₃]⁺: 385.1736 found: 385.1725. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 11.0 min, major enantiomer *tr* = 17.8 min. [α]_D²⁵ = 38.7 (c = 0.4, CHCl₃).

4.11 Synthesis of (*S*)-4,4,5,5-tetramethyl-2-((3-(4-(trifluoromethyl)benzyl)-2,3-dihydrobenzofuran-3-yl)methyl)-1,3,2-dioxaborolane (**2k**).



Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1k** (125.5 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2k** as a colorless ropy liquid (103.4 mg, 82% yield) with 93% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.44 (d, *J* = 8.0 Hz, 2H), 7.14-7.05 (m, 1H), 6.99 (d, *J* = 8.0 Hz, 2H), 6.88-6.77 (m, 2H), 6.71 (d, *J* = 8.0 Hz, 1H), 4.50 (d, *J* = 9.0 Hz, 1H), 4.35 (d, *J* = 8.9 Hz, 1H), 2.99 (s, 2H), 1.35 (d, *J* = 15.7 Hz, 1H), 1.27 (d, *J* = 15.3 Hz, 1H), 1.19 (s, 6H), 1.16 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.51, 141.76, 133.99, 130.73, 128.53 (d, *J* = 32.2 Hz), 128.25, 124.55 (q, *J* = 3.7 Hz), 124.29 (q, *J* = 272.9 Hz), 123.94, 119.98, 109.55, 83.34, 81.66, 47.48, 46.65, 24.74, 24.65. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.25. MS (EI): *m/z* (%) = 418 (M⁺, 1.40), 259 (100); HRMS calculated for [C₂₃H₂₆BF₃O₃]⁺: 418.1972 found: 418.1930. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 9.3 min, major enantiomer *tr* = 16.0 min. [α]_D²⁵ = 24.7 (c = 0.4, CHCl₃).


4.12 Synthesis of (*S*)-2-((3-(3-fluorobenzyl)-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**2l**).



Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1l** (110.5 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2l** as a colorless ropy liquid (99.5 mg, 90% yield)

with 92% *ee*. ^1H NMR (400 MHz, CDCl_3) δ 7.10-6.95 (m, 2H), 6.83-6.75 (m, 2H), 6.72 (t, $J = 7.4$ Hz, 1H), 6.60 (t, $J = 7.4$ Hz, 2H), 6.52 (d, $J = 10.1$ Hz, 1H), 4.41 (d, $J = 8.9$ Hz, 1H), 4.24 (d, $J = 9.0$ Hz, 1H), 2.85 (s, 2H), 1.26 (d, $J = 15.7$ Hz, 1H), 1.18 (d, $J = 16.4$ Hz, 1H), 1.09 (s, 6H), 1.07 (s, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 162.25 (d, $J = 245.0$ Hz), 159.54, 140.20 (d, $J = 7.3$ Hz), 134.26, 128.98 (d, $J = 8.4$ Hz), 128.13, 126.11 (d, $J = 2.9$ Hz), 123.88, 119.92, 117.23 (d, $J = 21.0$ Hz), 113.12 (d, $J = 20.9$ Hz), 109.43, 83.25, 81.65, 47.46, 46.54 (d, $J = 2.0$ Hz), 24.71, 24.62. ^{19}F NMR (376 MHz, CDCl_3) δ -114.10. MS (EI): m/z (%) = 369 ($\text{M}+\text{H}^+$, 0.32), 259 (100); HRMS calculated for $[\text{C}_{22}\text{H}_{27}\text{BFO}_3]^+$: 369.2032 found: 369.2022. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer $t_r = 10.7$ min, major enantiomer $t_r = 15.4$ min. $[\alpha]_{\text{D}}^{25} = 28.9$ ($c = 0.4$, CHCl_3).


4.13 Synthesis of (*S*)-2-((3-(3-chlorobenzyl)-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**2m**).



2m

Prepared according to typical procedure at 80 °C for 12 h by using $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1m** (115.4 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μL , 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2m** as a colorless ropy liquid (102.9 mg, 89% yield) with 90% *ee*. ^1H NMR (400 MHz, CDCl_3) δ 7.07 (d, $J = 8.1$ Hz, 1H), 7.01 (t, $J = 7.7$ Hz, 2H), 6.81 (d, $J = 9.3$ Hz, 2H), 6.73 (t, $J = 7.4$ Hz, 1H), 6.68 (d, $J = 7.5$ Hz, 1H), 6.62 (d, $J = 8.0$ Hz, 1H), 4.40 (d, $J = 8.9$ Hz, 1H), 4.24 (d, $J = 9.1$ Hz, 1H), 2.82 (s, 2H), 1.24 (d, $J = 15.4$ Hz, 1H), 1.13 (d, $J = 16.0$ Hz, 1H), 1.10 (s, 6H), 1.07 (s, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 159.51, 139.70, 134.19, 133.41, 130.50, 128.85, 128.55, 128.17, 126.41, 123.89, 119.91, 109.45, 83.26, 81.65, 47.43, 46.45, 24.74, 24.63. MS (EI): m/z (%) = 385 ($\text{M}+\text{H}^+$, 0.33), 259 (100); HRMS calculated for $[\text{C}_{22}\text{H}_{27}\text{BClO}_3]^+$: 385.1736 found: 385.1726. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer $t_r = 10.6$ min, major enantiomer $t_r = 15.3$ min. $[\alpha]_{\text{D}}^{25} = 30.0$ ($c = 0.4$, CHCl_3).

4.14 Synthesis of (*S*)-4,4,5,5-tetramethyl-2-((3-(3-nitrobenzyl)-2,3-dihydrobenzofuran-3-yl)methyl)-1,3,2-dioxaborolane (**2n**).




2n

Prepared according to typical procedure at 80 °C for 12 h by using $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1n** (118.6 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μL , 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2n** as a white soild (73.6 mg, 62% yield) with 90% *ee*. ^1H NMR (400 MHz, CDCl_3) δ 8.02-7.86 (m, 1H), 7.71 (t, $J = 2.0$ Hz, 1H), 7.23 (t, $J = 7.9$ Hz, 1H),

7.09-6.97 (m, 2H), 6.83-6.71 (m, 2H), 6.59 (d, $J = 8.0$ Hz, 1H), 4.42 (d, $J = 9.0$ Hz, 1H), 4.25 (d, $J = 9.0$ Hz, 1H), 3.10-2.77 (m, 2H), 1.29 (d, $J = 15.8$ Hz, 1H), 1.19 (d, $J = 11.3$ Hz, 1H), 1.15 (s, 6H), 1.12 (s, 6H). ^{13}C NMR (101 MHz, Chloroform- d) δ 159.50, 147.68, 139.67, 136.44, 133.58, 128.50, 128.40, 125.13, 123.70, 121.45, 120.16, 109.64, 83.48, 81.58, 47.52, 46.37, 24.76, 24.68. MS (EI): m/z (%) = 395 ($\text{M}+\text{H}^+$, 1.63), 259 (100); HRMS calculated for $[\text{C}_{22}\text{H}_{27}\text{BNO}_5]^+$: 395.1904 found: 395.1908. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 95:5, 0.5 mL/min, 220 nm); minor enantiomer $t_r = 14.9$ min, major enantiomer $t_r = 19.3$ min. $[\alpha]_{\text{D}}^{20} = 24.6$ ($c = 0.4$, acetone).


4.15 Synthesis of (*S*)-4,4,5,5-tetramethyl-2-((3-(3-methylbenzyl)-2,3-dihydrobenzofuran-3-yl)methyl)-1,3,2-dioxaborolane (**2o**).



2o

Prepared according to typical procedure at 80 °C for 12 h by using $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1o** (109.2 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μL , 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2o** as a colorless ropy liquid (92.3 mg, 85% yield) with 93% *ee*. ^1H NMR (400 MHz, CDCl_3) δ 7.11-7.03 (m, 2H), 6.99 (d, $J = 7.6$ Hz, 1H), 6.93-6.88 (m, 1H), 6.83-6.77 (m, 1H), 6.76-6.68 (m, 3H), 4.52 (d, $J = 8.8$ Hz, 1H), 4.33 (d, $J = 8.8$ Hz, 1H), 2.90 (s, 2H), 2.24 (s, 3H), 1.32 (d, $J = 15.7$ Hz, 1H), 1.23 (d, $J = 15.6$ Hz, 1H), 1.16 (s, 6H), 1.13 (s, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 159.61, 137.56, 137.08, 134.82, 131.41, 127.91, 127.57, 127.50, 126.95, 124.07, 119.75, 109.29, 83.14, 81.72, 47.47, 46.92, 24.73, 24.63, 21.29. MS (EI): m/z (%) = 365 ($\text{M}+\text{H}^+$, 0.50), 259 (100); HRMS calculated for $[\text{C}_{23}\text{H}_{30}\text{BO}_3]^+$: 365.2283 found: 365.2274. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer $t_r = 11.5$ min, major enantiomer $t_r = 14.9$ min. $[\alpha]_{\text{D}}^{25} = 28.8$ ($c = 0.4$, CHCl_3).

4.16 Synthesis of (*S*)-2-((3-(3-methoxybenzyl)-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**2p**).




2p

Prepared according to typical procedure at 80 °C for 12 h by using $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1p** (114.1 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μL , 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2p** as a colorless ropy liquid (70.2 mg, 62% yield) with 93% *ee*. ^1H NMR (400 MHz, CDCl_3) δ 7.07-6.97 (m, 2H), 6.88-6.80 (m, 1H), 6.78-6.69 (m, 1H), 6.68-6.59 (m, 2H), 6.48 (d, $J = 7.6$ Hz, 1H), 6.35-6.28 (m, 1H), 4.44 (d, $J = 8.9$ Hz, 1H), 4.25 (d, $J = 8.8$ Hz, 1H), 3.57 (s, 3H), 2.84 (s, 2H), 1.32-1.25 (m, 1H), 1.18 (s, 1H), 1.09 (s, 6H), 1.07


(s, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 159.63, 158.93, 139.19, 134.69, 128.58, 127.97, 124.06, 122.94, 119.80, 115.71, 112.23, 109.37, 83.19, 81.70, 54.95, 47.52, 46.99, 24.72, 24.67. MS (EI): m/z (%) = 380 (M^+ , 1.94), 259 (100); HRMS calculated for $[\text{C}_{23}\text{H}_{29}\text{BO}_4]^+$: 381.2232 found: 381.2221. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer t_r = 9.4 min, major enantiomer t_r = 12.1 min. $[\alpha]_{\text{D}}^{25}$ = 21.4 (c = 0.4, CHCl_3).

4.17 Synthesis of (*S*)-2-((3-(3-(tert-butyl)benzyl)-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**2q**).



Prepared according to typical procedure at 80 °C for 12 h by using $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1q** (121.9 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μL , 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2q** as a colorless ropy liquid (114.6 mg, 94% yield) with 92% *ee*. ^1H NMR (400 MHz, CDCl_3) δ 7.25-7.11 (m, 2H), 7.10-7.03 (m, 1H), 6.89-6.74 (m, 4H), 6.72-6.66 (m, 1H), 4.52 (d, J = 8.8 Hz, 1H), 4.34 (d, J = 8.8 Hz, 1H), 3.12-2.83 (m, 2H), 1.32 (d, J = 7.2 Hz, 1H), 1.25-1.22 (m, 1H), 1.20 (s, 9H), 1.18 (s, 6H), 1.15 (s, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 159.60, 150.22, 137.08, 134.62, 127.88, 127.82, 127.60, 127.32, 124.23, 123.08, 119.77, 109.30, 83.16, 81.92, 47.54, 47.12, 34.36, 31.22, 24.72. MS (EI): m/z (%) = 407 ($\text{M}+\text{H}^+$, 0.33), 259 (100); HRMS calculated for $[\text{C}_{26}\text{H}_{36}\text{BO}_3]^+$: 407.2752 found: 404.2744. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer t_r = 9.3 min, major enantiomer t_r = 12.6 min. $[\alpha]_{\text{D}}^{25}$ = 24.6 (c = 0.4, CHCl_3).


4.18 Synthesis of (*S*)-4,4,5,5-tetramethyl-2-((3-(2-methylbenzyl)-2,3-dihydrobenzofuran-3-yl)methyl)-1,3,2-dioxaborolane (**2r**).



Prepared according to typical procedure at 80 °C for 12 h by using $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1r** (109.2 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μL , 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2r** as a white soild (77.7 mg, 71% yield) with 94% *ee*. ^1H NMR (400 MHz, CDCl_3) δ 7.12-7.00 (m, 4H), 6.96-6.92 (m, 1H), 6.74-6.69 (m, 2H), 6.65-6.54 (m, 1H), 4.48 (d, J = 8.8 Hz, 1H), 4.39 (d, J = 8.9 Hz, 1H), 3.09 (d, J = 13.5 Hz, 1H), 2.88 (d, J = 13.5 Hz, 1H), 1.81 (s, 3H), 1.47 (d, J = 15.8 Hz, 1H), 1.27 (d, J = 12.7 Hz, 1H), 1.18 (s, 6H), 1.15 (s, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 159.57, 137.65, 135.99, 134.64, 131.06, 130.14, 127.91, 126.30, 125.13, 124.00, 119.93, 109.23, 83.23, 82.38, 47.84, 42.35, 24.76, 24.62, 19.47. MS (EI):


m/z (%) = 365 ($M+H^+$, 0.34), 259 (100); HRMS calculated for $[C_{23}H_{30}BO_3]^+$: 365.2283 found: 365.2277. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer tr = 10.6 min, major enantiomer tr = 15.8 min. $[\alpha]_D^{25}$ = 34.2 (c = 0.4, $CHCl_3$).

4.19 Synthesis of (*S*)-2-((3-(3,5-difluorobenzyl)-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**2s**).



Prepared according to typical procedure at 80 °C for 12 h by using $Pd_2(dba)_3 \cdot CHCl_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1s** (115.9 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μ L, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2s** as a colorless ropy liquid (101.7 mg, 88% yield) with 92% *ee*. 1H NMR (400 MHz, $CDCl_3$) δ 7.12 (d, J = 7.9 Hz, 1H), 6.91 (d, J = 7.3 Hz, 1H), 6.83 (t, J = 7.3 Hz, 1H), 6.72 (s, 1H), 6.63 (t, J = 9.0 Hz, 1H), 6.41 (d, J = 6.5 Hz, 2H), 4.47 (d, J = 9.0 Hz, 1H), 4.32 (d, J = 8.9 Hz, 1H), 2.92 (d, J = 1.7 Hz, 2H), 1.36 (d, J = 16.2 Hz, 1H), 1.27 (d, J = 15.9 Hz, 1H), 1.20 (s, 6H), 1.17 (s, 6H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 162.28 (dd, J = 247.4, 12.9 Hz), 159.48, 141.53 (t, J = 9.1 Hz), 133.88, 128.38, 123.74, 120.11, 113.15 (dd, J = 24.6, 11.9 Hz), 109.58, 101.80 (t, J = 25.3 Hz), 83.38, 81.59, 47.46, 46.47, 24.76, 24.66. ^{19}F NMR (376 MHz, $CDCl_3$) δ -111.05. MS (EI): m/z (%) = 386 (M^+ , 2.08), 259 (100); HRMS calculated for $[C_{22}H_{25}BF_2O_3]^+$: 386.1865 found: 386.1867. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer tr = 9.6 min, major enantiomer tr = 15.3 min. $[\alpha]_D^{25}$ = 21.8 (c = 0.4, $CHCl_3$).


4.20 Synthesis of (*S*)-4,4,5,5-tetramethyl-2-((3-(3,4,5-trifluorobenzyl)-2,3-dihydrobenzofuran-3-yl)methyl)-1,3,2-dioxaborolane (**2t**).



Prepared according to typical procedure at 80 °C for 12 h by using $Pd_2(dba)_3 \cdot CHCl_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1t** (121.3 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μ L, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2t** as a colorless ropy liquid (86 mg, 71% yield) with 94% *ee*. 1H NMR (400 MHz, $CDCl_3$) δ 7.12 (t, J = 7.6 Hz, 1H), 6.95-6.79 (m, 2H), 6.70 (d, J = 8.0 Hz, 1H), 6.52-6.40 (m, 2H), 4.44 (d, J = 9.0 Hz, 1H), 4.31 (d, J = 9.0 Hz, 1H), 2.86 (s, 2H), 1.36 (d, J = 15.6 Hz, 1H), 1.25 (s, 1H), 1.21 (s, 6H), 1.18 (s, 6H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 159.50, 150.34 (ddd, J = 248.8, 9.8, 4.0 Hz), 138.47 (dt, J = 249.8, 15.3 Hz), 133.93 (td, J = 7.3, 4.8 Hz), 133.57, 128.51, 123.63, 120.18, 114.14 (dd, J = 15.5, 5.3 Hz), 109.65, 83.45, 81.42, 47.44, 46.13, 24.75, 24.66. ^{19}F NMR (376 MHz, $CDCl_3$) δ -135.68 (d, J = 20.6 Hz), -163.79 (t, J =


20.7 Hz). MS (EI): m/z (%) = 404 (M^+ , 1.58), 259 (100); HRMS calculated for $[C_{22}H_{24}BF_3O_3]^+$: 404.1771 found: 404.1766. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer tr = 9.8 min, major enantiomer tr = 18.1 min. $[\alpha]_D^{25}$ = 19.2 (c = 0.4, $CHCl_3$).

4.21 Synthesis of (*S*)-4,4,5,5-tetramethyl-2-((3-(naphthalen-1-ylmethyl)-2,3-dihydrobenzofuran-3-yl)methyl)-1,3,2-dioxaborolane (**2u**).



Prepared according to typical procedure at 80 °C for 12 h by using $Pd_2(dba)_3 \cdot CHCl_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1u** (120.0 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μ L, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2u** as a white solid (107.8 mg, 90% yield) with 92% *ee*. 1H NMR (400 MHz, $CDCl_3$) δ 7.79 (s, 1H), 7.68 (d, J = 7.7 Hz, 1H), 7.58 (d, J = 8.2 Hz, 1H), 7.34-7.25 (m, 1H), 7.25-7.19 (m, 1H), 7.19-7.13 (m, 1H), 7.00-6.92 (m, 1H), 6.88 (d, J = 6.6 Hz, 1H), 6.67 (d, J = 7.2 Hz, 1H), 6.59 (t, J = 8.6 Hz, 2H), 4.46 (d, J = 8.9 Hz, 1H), 4.22 (d, J = 8.9 Hz, 1H), 3.52 (d, J = 13.8 Hz, 1H), 3.20 (d, J = 13.7 Hz, 1H), 1.39 (d, J = 15.9 Hz, 1H), 1.25 (d, J = 15.8 Hz, 1H), 1.10 (s, 6H), 1.07 (s, 6H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 159.44, 135.01, 134.07, 133.65, 133.29, 128.66, 128.46, 127.92, 127.03, 125.27, 124.99, 124.83, 124.34, 123.96, 119.96, 109.34, 83.26, 81.60, 48.28, 41.82, 24.83, 24.60. MS (EI): m/z (%) = 401 ($M+H^+$, 0.21), 259 (100); HRMS calculated for $[C_{26}H_{30}BO_3]^+$: 401.2283 found: 401.2273. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer tr = 14.4 min, major enantiomer tr = 24.9 min. $[\alpha]_D^{25}$ = -34.7 (c = 0.4, $CHCl_3$).


4.22 Synthesis of (*S*)-2-((3-(dibenzo[b,d]thiophen-4-ylmethyl)-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**2v**).



Prepared according to typical procedure at 80 °C for 12 h by using $Pd_2(dba)_3 \cdot CHCl_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1v** (136.9 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μ L, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2v** as a colorless ropy liquid (112.2 mg, 82% yield) with 90% *ee*. 1H NMR (400 MHz, $CDCl_3$) δ 8.12-8.01 (m, 1H), 7.95 (s, 1H), 7.83-7.70 (m, 1H), 7.47-7.32 (m, 2H), 7.23 (t, J = 7.8 Hz, 1H), 7.08 (t, J = 7.7 Hz, 1H), 6.97 (d, J = 7.3 Hz, 1H), 6.86-6.73 (m, 2H), 6.70 (d, J = 8.0 Hz, 1H), 4.65 (d, J = 9.0 Hz, 1H), 4.38 (d, J = 9.0 Hz, 1H), 3.32-3.17 (m, 2H), 1.54-1.38 (m, 2H), 1.17 (s, 6H), 1.13 (s, 6H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 159.68, 141.40, 138.99, 136.07, 135.51, 134.56, 132.57, 128.38, 128.16, 126.46, 124.19, 123.83,

122.50, 121.55, 120.10, 119.74, 109.49, 83.27, 81.62, 48.39, 46.10, 24.81, 24.60. MS (EI): m/z (%) = 456 (M^+ , 1.11), 259 (100); HRMS calculated for $[C_{28}H_{30}BO_3Si]^+$: 457.2003 found: 457.1996. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer tr = 20.6 min, major enantiomer tr = 30.2 min. $[\alpha]_D^{25} = -46.1$ ($c = 0.4$, $CHCl_3$).


4.23 Synthesis of (*S*)-trimethyl((3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-2,3-dihydrobenzofuran-3-yl)methyl)silane (**2w**).



2w

Prepared according to typical procedure at 80 °C for 12 h by using $Pd_2(dba)_3 \cdot CHCl_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1w** (103.8 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μ L, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2w** as a colorless ropy liquid (93.3 mg, 90% yield) with 92% *ee*. 1H NMR (400 MHz, $CDCl_3$) δ 7.30-7.15 (m, 2H), 7.00-6.81 (m, 2H), 4.54 (d, $J = 8.7$ Hz, 1H), 4.45 (d, $J = 8.7$ Hz, 1H), 1.52 (d, $J = 15.2$ Hz, 1H), 1.45-1.36 (m, 2H), 1.28 (s, 6H), 1.25 (s, 6H), 1.19 (d, $J = 14.7$ Hz, 1H), 0.00 (s, 9H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 158.97, 137.32, 127.62, 123.23, 120.16, 109.35, 83.71, 83.04, 45.56, 32.05, 24.70. MS (EI): m/z (%) = 346 (M^+ , 5.71), 259 (100); HRMS calculated for $[C_{19}H_{31}BO_3Si]^+$: 346.2136 found: 346.2139. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer tr = 9.0 min, major enantiomer tr = 11.8 min. $[\alpha]_D^{25} = 6.1$ ($c = 0.4$, $CHCl_3$).

4.24 Synthesis of (*S*)-2-((3-(4-chlorobutyl)-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**2x**).




2x

Prepared according to typical procedure at 80 °C for 12 h by using $Pd_2(dba)_3 \cdot CHCl_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1x** (105.2 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μ L, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2x** as a colorless ropy liquid (87.9 mg, 84% yield) with 97% *ee*. 1H NMR (400 MHz, $CDCl_3$) δ 7.10 (dd, $J = 12.2, 7.5$ Hz, 2H), 6.84 (t, $J = 7.4$ Hz, 1H), 6.74 (d, $J = 7.9$ Hz, 1H), 4.38 (s, 2H), 3.46 (t, $J = 6.8$ Hz, 2H), 1.77-1.56 (m, 4H), 1.47 (q, $J = 14.8, 13.5$ Hz, 1H), 1.38-1.20 (m, 3H), 1.16 (s, 6H), 1.14 (s, 6H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 159.53, 135.06, 127.86, 123.21, 120.17, 109.33, 83.14, 82.09, 46.42, 44.63, 40.70, 32.93, 24.68, 24.64, 21.91. MS (EI): m/z (%) = 350 (M^+ , 16.07), 259 (100); HRMS calculated for $[C_{19}H_{28}BClO_3]^+$: 350.1820 found: 350.1816. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer tr = 11.6 min, major enantiomer tr = 19.0 min. $[\alpha]_D^{25} = 20.9$ ($c = 0.4$, $CHCl_3$).


4.25 Synthesis of (*S*)-2-(4-(3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-2,3-

dihydrobenzofuran-3-yl)butyl)isoindoline-1,3-dione (**2y**).




Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1y** (138.3 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2y** as a colorless ropy liquid (101.6 mg, 74% yield) with 90% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.88-7.77 (m, 2H), 7.73-7.65 (m, 2H), 7.15-7.00 (m, 2H), 6.82 (t, *J* = 7.3 Hz, 1H), 6.72 (d, *J* = 7.9 Hz, 1H), 4.38 (s, 2H), 3.60 (t, *J* = 7.5 Hz, 2H), 1.82-1.53 (m, 4H), 1.44-1.18 (m, 4H), 1.15 (s, 6H), 1.13 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 168.19, 159.47, 134.96, 133.73, 132.02, 127.74, 123.20, 123.03, 120.09, 109.19, 83.06, 81.97, 46.37, 40.95, 37.65, 28.85, 24.63, 24.57, 21.75. MS (EI): *m/z* (%) = 461 (M+H⁺, 13.22), 259 (100); HRMS calculated for [C₂₇H₃₂BNO₅]⁺: 461.2374 found: 461.2376. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 18.0 min, major enantiomer *tr* = 21.8 min. [α]_D²⁵ = 24.4 (c = 0.4, CHCl₃).

4.26 Synthesis of (*R*)-3-methyl-1-((3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-2,3-dihydrobenzofuran-3-yl)methyl)-1H-indole (**2z**).




Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1z** (121.0 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **2z** as a colorless ropy liquid (66.0 mg, 55% yield) with 92% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.53-7.45 (m, 1H), 7.17-7.01 (m, 4H), 6.99-6.92 (m, 1H), 6.88-6.71 (m, 2H), 6.53 (s, 1H), 4.53 (d, *J* = 9.2 Hz, 1H), 4.27 (ddd, *J* = 29.2, 16.0, 9.6 Hz, 3H), 2.27-2.23 (m, 3H), 1.44 (d, *J* = 16.0 Hz, 1H), 1.35 (d, *J* = 15.9 Hz, 1H), 1.19 (s, 6H), 1.15 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.76, 137.71, 133.05, 128.68, 128.24, 126.62, 124.03, 121.34, 120.42, 118.71, 118.49, 110.47, 109.70, 109.39, 83.51, 80.20, 53.92, 49.24, 24.85, 24.59, 9.51. MS (EI): *m/z* (%) = 404 (M+H⁺, 6.92), 145 (100); HRMS calculated for [C₂₅H₃₁BNO₃]⁺: 404.2392 found: 404.2382. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 13.5 min, major enantiomer *tr* = 19.5 min. [α]_D²⁵ = -14.2 (c = 0.4, CHCl₃).

4.27 Synthesis of (*S*)-4,4,5,5-tetramethyl-2-((3-phenyl-2,3-dihydrobenzofuran-3-yl)methyl)-1,3,2-dioxaborolane (**2aa**).




Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **1aa** (100.9 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol), H₂O (22 μL, 1.2 mmol) and EA (3 mL), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **1aa** as a colorless ropy liquid (51.8 mg, 52% yield) with 82% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.32-7.22 (m, 4H), 7.19-7.09 (m, 3H), 6.92-6.77 (m, 2H), 4.77-4.68 (m, 2H), 1.84 (d, *J* = 15.4 Hz, 1H), 1.61 (d, *J* = 15.4 Hz, 1H), 1.05 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 159.60, 147.65, 135.70, 128.21, 128.13, 126.17, 126.07, 124.71, 120.60, 109.69, 85.44, 83.20, 50.94, 24.60, 24.48. ESI-MS calculated for C₂₁H₂₅BNaO₃: *m/z* (%): 359.1789 (M+Na⁺), found: 359.1791. Enantiomeric excess was determined by HPLC with a Chiralpak OJH column (hexanes : 2-propanol = 90:10, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 16.5 min, major enantiomer *tr* = 22.0 min. [α]_D²⁰ = -3.1 (c = 0.3, CHCl₃).

4.28 Synthesis of (*R*)-2-((5-fluoro-3-methyl-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**4a**).



Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **3a** (87.6 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **4a** as a colorless ropy liquid (80.2 mg, 92% yield) with 90% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 6.86 (dd, *J* = 8.2, 2.7 Hz, 1H), 6.75 (td, *J* = 8.8, 2.8 Hz, 1H), 6.64 (dd, *J* = 8.6, 4.1 Hz, 1H), 4.41 (d, *J* = 8.6 Hz, 1H), 4.25 (d, *J* = 8.6 Hz, 1H), 1.36 (s, 3H), 1.33-1.25 (m, 2H), 1.21 (s, 6H), 1.20 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 157.55 (d, *J* = 236.6 Hz), 154.84 (d, *J* = 1.5 Hz), 138.78 (d, *J* = 7.8 Hz), 113.67 (d, *J* = 24.2 Hz), 109.89 (d, *J* = 24.6 Hz), 109.49 (d, *J* = 8.4 Hz), 84.72, 83.25, 43.58, 27.61, 24.74, 24.70. ¹⁹F NMR (282 MHz, CDCl₃) δ -124.34. MS (EI): *m/z* (%) = 292 (M⁺, 20.62), 151 (100); HRMS calculated for [C₁₆H₂₂BFO₃]⁺: 292.1646 found: 292.1642. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 8.9 min, major enantiomer *tr* = 9.7 min. [α]_D²⁰ = 14.3 (c = 0.4, acetone).


4.29 Synthesis of (*R*)-2-((5-chloro-3-methyl-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**4b**).



Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **3b** (92.6 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **4b** as a colorless ropy liquid (79.7 mg, 86% yield)

with 90% *ee*. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.04 (d, $J = 2.3$ Hz, 1H), 6.97-6.91 (m, 1H), 6.58 (d, $J = 8.4$ Hz, 1H), 4.33 (d, $J = 8.7$ Hz, 1H), 4.18 (d, $J = 8.6$ Hz, 1H), 1.29 (s, 3H), 1.20 (d, $J = 15.5$ Hz, 2H), 1.13 (s, 6H), 1.12 (s, 6H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 157.70, 139.20, 127.49, 124.92, 123.08, 110.41, 84.77, 83.27, 43.43, 27.70, 24.77, 24.69. MS (EI): m/z (%) = 309 ($\text{M}+\text{H}^+$, 6.67), 167 (100); HRMS calculated for $[\text{C}_{16}\text{H}_{23}\text{BClO}_3]^+$: 309.1423 found: 309.1427. Enantiomeric excess was determined by HPLC with a Chiralpak AD-3 column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer $t_r = 10.3$ min, major enantiomer $t_r = 11.1$ min. $[\alpha]_{\text{D}}^{25} = 34.2$ ($c = 0.4$, CHCl_3).


4.30 Synthesis of (*R*)-2-((3,5-dimethyl-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**4c**).



4c

Prepared according to typical procedure at 80 °C for 12 h by using $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **3c** (86.5 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μL , 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **4c** as a colorless ropy liquid (77.3 mg, 89% yield) with 90% *ee*. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 6.87 (d, $J = 1.9$ Hz, 1H), 6.82-6.76 (m, 1H), 6.56 (d, $J = 8.1$ Hz, 1H), 4.31 (d, $J = 8.6$ Hz, 1H), 4.14 (d, $J = 8.6$ Hz, 1H), 2.19 (s, 3H), 1.28 (s, 3H), 1.21 (d, $J = 15.5$ Hz, 2H), 1.12 (s, 6H), 1.11 (s, 6H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 156.86, 137.27, 129.44, 127.99, 123.14, 108.93, 84.21, 83.10, 43.14, 27.83, 24.76, 24.67, 20.82. MS (EI): m/z (%) = 289 ($\text{M}+\text{H}^+$, 3.42), 147 (100); HRMS calculated for $[\text{C}_{17}\text{H}_{26}\text{BO}_3]^+$: 289.1970 found: 289.1965. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer $t_r = 11.2$ min, major enantiomer $t_r = 15.5$ min. $[\alpha]_{\text{D}}^{25} = 32.8$ ($c = 0.4$, CHCl_3).


4.31 Synthesis of (*R*)-4,4,5,5-tetramethyl-2-((3-methyl-5-phenyl-2,3-dihydrobenzofuran-3-yl)methyl)-1,3,2-dioxaborolane (**4d**).



4d

Prepared according to typical procedure at 80 °C for 12 h by using $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **3d** (105.1 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μL , 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **4d** as a white soild (97.7 mg, 93% yield) with 95% *ee*. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.48-7.41 (m, 2H), 7.35-7.27 (m, 3H), 7.26-7.21 (m, 1H), 7.18 (t, $J = 7.4$ Hz, 1H), 6.73 (d, $J = 8.3$ Hz, 1H), 4.39 (d, $J = 8.6$ Hz, 1H), 4.22 (d, $J = 8.6$ Hz, 1H), 1.33 (s, 3H), 1.26 (d, $J = 15.5$ Hz, 1H), 1.18 (d, $J = 15.2$ Hz, 1H), 1.09 (s, 6H), 1.08 (s, 6H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 158.80, 141.56, 137.88, 133.88, 128.57, 126.77, 126.70, 126.31, 121.64, 109.54, 84.61, 83.16, 43.19, 28.22, 24.73. MS (EI): m/z (%) = 350 (M^+ , 58.53), 209 (100); HRMS calculated for $[\text{C}_{22}\text{H}_{27}\text{BO}_3\text{Na}]^+$: 373.1945 found: 373.1938. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer $t_r = 11.2$ min, major enantiomer $t_r = 12.9$ min. $[\alpha]_{\text{D}}^{25} = -65.5$ ($c = 0.4$, CHCl_3).


4.32 Synthesis of (*R*)-4,4,5,5-tetramethyl-2-((3-methyl-5-(2-phenylpropan-2-yl)-2,3-dihydrobenzofuran-3-yl)methyl)-1,3,2-dioxaborolane (**4e**).



4e

Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **3e** (117.6 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **4e** as a colorless ropy liquid (113.1 mg, 96% yield) with 92% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.19-7.11 (m, 4H), 7.10-7.01 (m, 1H), 6.97 (d, *J* = 2.1 Hz, 1H), 6.88-6.80 (m, 1H), 6.55 (d, *J* = 8.3 Hz, 1H), 4.31 (d, *J* = 8.6 Hz, 1H), 4.15 (d, *J* = 8.5 Hz, 1H), 1.57 (s, 6H), 1.25 (s, 3H), 1.15 (t, *J* = 16.1 Hz, 2H), 1.09 (s, 6H), 1.08 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 156.90, 151.19, 142.80, 136.75, 127.81, 126.66, 126.27, 125.36, 120.94, 108.48, 84.47, 83.06, 43.22, 42.57, 31.14, 27.95, 24.76, 24.70. MS (EI): *m/z* (%) = 392 (M⁺, 58.25), 377 (100); HRMS calculated for [C₂₅H₃₃BO₃]⁺: 392.2523 found: 392.2518. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 10.9 min, major enantiomer *tr* = 9.5 min. [α]_D²⁰ = 23.5 (*c* = 0.4, acetone).


4.33 Synthesis of (*R*)-2-((5-(tert-butyl)-3-methyl-2,3-dihydrobenzofuran-3-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**4f**).



4f

Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **3f** (99.1 mg, 0.3 mmol), B₂Pin₂ (83.8 mg, 0.33 mmol), Cs₂CO₃ (195.5 mg, 0.6 mmol) and H₂O (22 μL, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **4f** as a colorless ropy liquid (90.2 mg, 91% yield) with 90% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.12 (d, *J* = 2.1 Hz, 1H), 7.06-7.00 (m, 1H), 6.60 (d, *J* = 8.3 Hz, 1H), 4.32 (d, *J* = 8.5 Hz, 1H), 4.16 (d, *J* = 8.5 Hz, 1H), 1.29 (s, 3H), 1.26 (d, *J* = 2.8 Hz, 1H), 1.21 (s, 9H), 1.16 (s, 1H), 1.12 (s, 6H), 1.10 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 156.79, 143.25, 136.72, 124.40, 119.55, 108.49, 84.48, 83.08, 43.27, 34.33, 31.75, 28.07, 24.78, 24.72. MS (EI): *m/z* (%) = 331 (M+H⁺, 9.23), 315 (100); HRMS calculated for [C₂₀H₃₂BO₃]⁺: 331.2439 found: 331.2431. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 8.8 min, major enantiomer *tr* = 9.2 min. [α]_D²⁵ = 31.8 (*c* = 0.4, CHCl₃).

4.34 Synthesis of (*R*)-4,4,5,5-tetramethyl-2-((3-methyl-2,3-dihydronaphtho[2,3-*b*]furan-3-yl)methyl)-1,3,2-dioxaborolane (**4g**).




4g

Prepared according to typical procedure at 80 °C for 12 h by using Pd₂(dba)₃•CHCl₃ (2.5 mol%),

N-Me-Xu3 (7.5 mol%) from allyl ether **3g** (97.3 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μ L, 1.2 mmol), after a flash column chromatography (hexanes: EA = 100:1) afforded the product **4g** as a white solid (76.1 mg, 78% yield) with 93% *ee*. 1H NMR (400 MHz, $CDCl_3$) δ 7.66-7.54 (m, 2H), 7.48 (s, 1H), 7.26 (d, J = 6.9 Hz, 1H), 7.20-7.14 (m, 1H), 6.98 (s, 1H), 4.40 (d, J = 8.5 Hz, 1H), 4.24 (d, J = 8.5 Hz, 1H), 1.37 (d, J = 1.4 Hz, 3H), 1.35-1.19 (m, 2H), 1.10 (s, 6H), 1.08 (s, 6H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 158.14, 140.29, 134.34, 129.63, 127.68, 126.66, 125.46, 122.94, 121.27, 103.71, 84.35, 83.23, 42.77, 27.98, 24.78, 24.69. MS (EI): m/z (%) = 325 ($M+H^+$, 11.31), 183 (100); HRMS calculated for $[C_{20}H_{26}BO_3]^+$: 325.1970 found: 325.1963. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 99:1, 0.5 mL/min, 220 nm); minor enantiomer tr = 12.0 min, major enantiomer tr = 14.5 min. $[\alpha]_D^{25}$ = 46.8 (c = 0.4, $CHCl_3$).


4.35 Synthesis of (*R*)-1-methyl-6-(phenylsulfonyl)-1-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-1,6-dihydro-2*H*-furo[3,2-*e*]indole (**4h**).



4h

Prepared according to typical procedure at 80 °C for 12 h by using $Pd_2(dba)_3 \cdot CHCl_3$ (2.5 mol%), **N-Me-Xu3** (7.5 mol%) from allyl ether **3h** (136 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μ L, 1.2 mmol), after a flash column chromatography (hexanes: EA = 6:1) afforded the product **4h** as a white solid (98.3 mg, 73% yield) with 80% *ee*. 1H NMR (400 MHz, $CDCl_3$) δ 7.86 (d, J = 7.5 Hz, 2H), 7.73 (d, J = 8.7 Hz, 1H), 7.56-7.47 (m, 2H), 7.41 (t, J = 7.5 Hz, 2H), 6.76 (d, J = 8.8 Hz, 1H), 6.66 (d, J = 2.7 Hz, 1H), 4.49 (d, J = 8.6 Hz, 1H), 4.27 (d, J = 8.6 Hz, 1H), 1.45 (s, 3H), 1.39 (d, J = 12.8 Hz, 1H), 1.32 (d, J = 15.6 Hz, 1H), 1.05 (s, 12H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 155.43, 138.29, 133.58, 130.46, 129.13, 127.30, 127.13, 126.78, 126.57, 112.60, 107.37, 106.17, 83.88, 83.11, 44.21, 27.64, 24.59. ESI-MS calculated for $C_{24}H_{28}BNNaO_5S$: m/z (%): 476.1673 ($M+Na^+$), found: 476.1680. Enantiomeric excess was determined by HPLC with a Chiralpak ADH column (hexanes : 2-propanol = 80:20, 0.5 mL/min, 250 nm); major enantiomer tr = 16.7 min, minor enantiomer tr = 20.1 min. $[\alpha]_D^{20}$ = 34.1 (c = 0.3, $CHCl_3$).

4.36 Synthesis of (*S*)-4,4,5,5-tetramethyl-2-((4-methylchroman-4-yl)methyl)-1,3,2-dioxaborolane (**4i**).




4i

Prepared according to typical procedure at 80 °C for 12 h by using $Pd_2(dba)_3 \cdot CHCl_3$ (2.5 mol%), **N-Me-Xu3** (7.5 mol%) from allyl ether **3i** (86.4 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μ L, 1.2 mmol), after a flash column chromatography (hexanes: EA = 20:1) afforded the product **4i** as a colorless oil (63.2 mg, 73% yield) with 85% *ee*. 1H NMR (400 MHz, $CDCl_3$) δ 7.29 (dd, J = 7.8, 1.6 Hz, 1 H), 7.03 (ddd, J = 8.2, 7.3, 1.6 Hz, 1 H), 6.85 (td, J = 7.7, 1.3 Hz, 1 H), 6.75 (dd, J = 8.1, 1.2 Hz, 1 H), 4.20 (dddd, J = 20.1, 13.9, 7.6, 3.2 Hz, 2 H), 2.25 (ddd, J = 13.6, 9.0, 3.6 Hz, 1 H), 1.80 (ddd, J = 13.9, 6.1, 2.9 Hz, 1 H), 1.40 (s, 3


H), 1.30 (s, 2 H), 1.16 (s, 6H), 1.12 (s, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 153.52, 132.53, 127.19, 126.79, 120.18, 116.63, 82.88, 63.05, 36.37, 32.06, 31.58, 24.72, 24.59. MS (EI): m/z (%) = 288 ($\text{M}+\text{H}^+$, 18.61), 147 (100); HRMS calculated for $[\text{C}_{17}\text{H}_{26}\text{BO}_3]^+$: 288.1897 found: 288.1902. Enantiomeric excess was determined by HPLC with a Chiralpak AD-3 column (hexanes : 2-propanol = 99.5:0.5, 0.3 mL/min, 254 nm); minor enantiomer t_r = 18.2 min, major enantiomer t_r = 19.4 min. $[\alpha]_{\text{D}}^{20}$ = 14.8 (c = 0.4, acetone).

4.37 Synthesis of (*S*)-4,4,5,5-tetramethyl-2-((1-methyl-2,3-dihydro-1H-inden-1-yl)methyl)-1,3,2-dioxaborolane (**4j**).



Prepared according to typical procedure at 80 °C for 12 h by using $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **3j** (81.6 mg, 0.3 mmol), B_2Pin_2 (83.8 mg, 0.33 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μL , 1.2 mmol), after a flash column chromatography (hexanes: EA = 20:1) afforded the product **4j** as a colorless oil (62.1 mg, 77% yield) with 89% *ee*. ^1H NMR (400 MHz, CDCl_3) δ 7.30-7.02 (m, 4 H), 2.88 (td, J = 7.2, 3.2 Hz, 2 H), 2.21-2.06 (m, 1 H), 1.94 (ddd, J = 12.5, 7.6, 6.2 Hz, 1 H), 1.31 (s, 3 H), 1.26 (d, J = 14.9 Hz, 1 H), 1.19 (s, 6H), 1.18 (s, 6H), 1.11 (d, J = 14.9 Hz, 1 H). ^{13}C NMR (101 MHz, CDCl_3) δ 153.36, 142.44, 126.12, 125.96, 124.26, 122.29, 82.80, 45.32, 40.76, 30.08, 28.68, 24.81, 24.74. MS (EI): m/z (%) = 272 ($\text{M}+\text{H}^+$, 4.49), 131 (100); HRMS calculated for $[\text{C}_{17}\text{H}_{26}\text{BO}_2]^+$: 272.1948 found: 272.1950. Enantiomeric excess was determined by HPLC with a Chiralpak AD-3 column (hexanes : 2-propanol = 99.5:0.5, 0.3 mL/min, 254 nm); minor enantiomer t_r = 12.3 min, major enantiomer t_r = 13.9 min. $[\alpha]_{\text{D}}^{20}$ = 23.0 (c = 0.4, acetone).


4.38 Synthesis of (*R*)-1-(3-methyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)indolin-1-yl)ethan-1-one (**4k**).



Prepared according to typical procedure at 80 °C for 12 h by using $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2.5 mol%), *N*-Me-Xu3 (7.5 mol%) from allyl ether **3k** (94.5 mg, 0.3 mmol), B_2Pin_2 (99 mg, 0.39 mmol), Cs_2CO_3 (195.5 mg, 0.6 mmol) and H_2O (22 μL , 1.2 mmol), after a flash column chromatography (hexanes: EA = 5:1) afforded the product **4k** as a yellow solid (87.1 mg, 92% yield) with 53% *ee*. ^1H NMR (400 MHz, CDCl_3) δ 8.15 (d, J = 7.9 Hz, 1H), 7.21-7.11 (m, 2H), 7.02 (t, J = 7.0 Hz, 1H), 4.06 (d, J = 10.2 Hz, 1H), 3.76 (d, J = 10.2 Hz, 1H), 2.22 (s, 3H), 1.39 (s, 3H), 1.26 (s, 1H), 1.24 (s, 1H), 1.11 (s, 12H). ^{13}C NMR (101 MHz, CDCl_3) δ 168.59, 141.52, 140.85, 127.47, 123.63, 122.04, 116.82, 83.14, 62.86, 41.48, 29.78, 24.70, 24.60, 24.18. ESI-MS calculated for $\text{C}_{18}\text{H}_{26}\text{BNNaO}_3$: m/z (%): 338.1898 ($\text{M}+\text{Na}^+$), found: 338.1905. Enantiomeric excess was determined by HPLC with a Chiralpak ADH column (hexanes : 2-propanol = 96:4, 0.5 mL/min, 220 nm); major enantiomer t_r = 29.9 min, minor enantiomer t_r = 33.6 min. $[\alpha]_{\text{D}}^{20}$ = -1.1 (c = 0.3, CHCl_3).


5. Synthetic Transformations

5.1 Synthesis of (*S*)-(3-methyl-5-phenyl-2,3-dihydrobenzofuran-3-yl)methanol (**5**).




The synthesis was conducted according to a modified literature procedure.^[9] An aqueous hydrogen peroxide solution (0.4 mL, 30% w/w) was added dropwise to a solution of **4d** (105 mg, 0.3 mmol) in THF and aqueous sodium phosphate monobasic (1.5 mL, 0.75 mmol, 0.5 M) at 0 °C. The mixture was stirred at 0 °C for 30 min and at room temperature for 1.5 h. Upon the completion of the reaction as determined by TLC, the mixture was cooled to 0 °C and quenched with water. The aqueous layer was extracted with EtOAc (3 x 5 mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated. The crude product was purified by column chromatography on silica gel (hexanes: EA = 5:1) to provide **5** as a colorless oil (45.4 mg, 99%) with 94% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.43 (d, *J* = 7.2 Hz, 2H), 7.36-7.26 (m, 3H), 7.25-7.16 (m, 2H), 6.77 (d, *J* = 8.3 Hz, 1H), 4.51 (d, *J* = 8.9 Hz, 1H), 4.12 (d, *J* = 8.8 Hz, 1H), 3.58 (d, *J* = 10.8 Hz, 1H), 3.49 (d, *J* = 10.9 Hz, 1H), 1.30 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 159.86, 141.08, 134.18, 132.53, 128.68, 127.81, 126.73, 126.59, 121.88, 109.93, 80.51, 68.91, 47.62, 21.82. ESI-MS calculated for C₁₆H₁₆NaO₂: *m/z* (%): 263.1042 (M+Na⁺), found: 263.1043. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 95:5, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 16.3 min, major enantiomer *tr* = 17.8 min. [α]_D²⁰ = 29.2 (*c* = 0.4, acetone).

5.2 Synthesis of (*R*)-trifluoro((3-methyl-5-phenyl-2,3-dihydrobenzofuran-3-yl)methyl)-λ⁴-borane, potassium salt (**6**).




The synthesis was conducted according to a modified literature procedure.^[10] The boronic ester **4d** (140 mg, 0.4 mmol) was dissolved in acetonitrile (2.5 mL) and saturated aqueous KHF₂ (4.5 M, 0.45 mL, 5.1 equiv) was added. The reaction mixture was stirred at room temperature for 3 h, concentrated, azeotroped with methanol, and placed on the vacuum for 3 h. The crude product was dissolved in hot acetone, filtered, and Then the solvent was removed under vacuum and the crude product was recrystallized from acetone to give the desired product **6** as a white solid (130.4 mg, 98%). ¹H NMR (400 MHz, Acetone-*d*6) δ 7.61-7.51 (m, 2H), 7.41-7.35 (m, 3H), 7.31-7.19 (m, 2H), 6.71 (d, *J* = 8.2 Hz, 1H), 4.48 (d, *J* = 8.6 Hz, 1H), 4.23 (d, *J* = 8.6 Hz, 1H), 1.33 (s, 3H), 0.89 (dq, *J* = 13.8, 6.8 Hz, 1H), 0.63 (dq, *J* = 13.7, 6.8 Hz, 1H). ¹³C NMR (101 MHz, Acetone-*d*6) δ 159.87, 143.44, 142.75, 133.96, 129.47, 127.26, 126.91, 126.26, 122.11, 109.74, 109.65, 86.01, 44.91 (d, *J* = 1.9 Hz), 28.30. ¹⁹F NMR (376 MHz, Acetone-*d*6) δ -135.50. ESI-MS calculated for C₁₆H₁₅BF₃KNaO: *m/z* (%):353.0700 (M+Na⁺), found: 353.0691. [α]_D²⁰ = 33.2 (*c* = 0.4, acetone).

5.3 Synthesis of (*R*)-3-allyl-3-methyl-5-phenyl-2,3-dihydrobenzofuran (**7**).



The synthesis was conducted according to a modified literature procedure.^[11] The boronic ester **4d** (140 mg, 0.4 mmol) was dissolved in THF (2.0 mL) under argon. The mixture was cooled to -78 °C, vinyl magnesium bromide (1.0 M in THF, 1.2 mL, 1.2 mmol) was added dropwise and the solution was stirred at room temperature for 2 h. Then a solution of I₂ (152 mg, 1.2 mmol) in MeOH (3.0 mL) was added dropwise at -78 °C. After 2 h, a solution of MeONa (108 mg, 2.0 mmol) in MeOH (3.0 mL) was dropwisely added at room temperature for 2 h. The reaction was quenched by the addition of saturated aqueous Na₂S₂O₃ (10 mL). The organic layer was separated and the aqueous phase extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine (10 mL), dried over magnesium sulfate and concentrated. The crude product was purified by column chromatography on silica gel (hexanes: EA = 50:1) to give **7** as a colorless oil (50 mg, 99%) with 92% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.46 (d, *J* = 7.4 Hz, 2H), 7.36-7.26 (m, 3H), 7.24-7.18 (m, 2H), 6.77 (d, *J* = 8.2 Hz, 1H), 5.75-5.54 (m, 1H), 5.03 (s, 1H), 4.99 (d, *J* = 6.7 Hz, 1H), 4.36 (d, *J* = 8.6 Hz, 1H), 4.10 (d, *J* = 8.6 Hz, 1H), 2.33 (d, *J* = 7.3 Hz, 2H), 1.31 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 159.25, 141.43, 135.53, 134.08, 133.89, 128.66, 127.23, 126.81, 126.50, 121.74, 118.45, 109.75, 82.32, 45.18, 45.10, 25.17. MS (ESI): *m/z* (%) = 250 (M+H⁺, 17.78); HRMS calculated for [C₂₀H₂₅BO₃]⁺: 250.1358 found: 250.1356. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 95:5, 0.5 mL/min, 220 nm); minor enantiomer *tr* = 11.5 min, major enantiomer *tr* = 10.6 min. [α]_D²⁰ = 85.0 (*c* = 0.2, acetone).


5.4 Synthesis of (*R*)-3-(furan-2-ylmethyl)-3-methyl-5-phenyl-2,3-dihydrobenzofuran (**8**).




The synthesis was conducted according to a modified literature procedure.^[11] *n*-BuLi (2.4 M in hexanes, 0.1 mL, 0.24 mmol) was added dropwise at -78 °C to a solution of furan (16.3 mg, 0.24 mmol) in THF (1.0 mL). The cooling bath was removed and the mixture was stirred at room temperature for 1 h. The mixture was cooled to -78 °C and boronic ester **4d** (70 mg, 0.2 mmol) was added dropwise as a solution in THF (1.0 mL). The mixture was stirred for 1 h at -78 °C and a solution of *N*-bromosuccinimide (42.7 mg, 0.24 mmol) in THF (1.0 mL) was added dropwise. After 1 h at -78 °C, a saturated aqueous solution of Na₂S₂O₃ was added and the reaction mixture was allowed to warm to room temperature. After addition of Et₂O and water, the layers were separated and the aqueous layer was extracted with Et₂O (3 x 5 mL). The combined organic layers were dried over MgSO₄ and concentrated in vacuo. The crude product was purified by column chromatography on silica gel (hexanes: EA = 50:1) to give **8** as a colorless oil (44 mg, 76%) with 95% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.56-7.47 (m, 2H), 7.43-7.35 (m, 3H), 7.34-7.32 (m, 1H), 7.31-7.25 (m, 1H), 7.23-7.19 (m, 1H), 6.85 (d, *J* = 8.2 Hz, 1H), 6.29 (t, *J* = 2.5 Hz, 1H), 5.97 (d, *J* = 3.1 Hz, 1H), 4.60 (d, *J* = 8.8 Hz, 1H), 4.19 (d, *J* = 8.8 Hz, 1H), 2.96 (s, 2H), 1.39 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 159.12, 152.50, 141.53, 141.35, 135.35, 134.06, 128.65, 127.38, 126.77, 126.51, 121.77, 110.21, 109.81, 107.88, 82.72, 45.84, 38.73, 24.82. MS (EI): *m/z* (%) =



290 (M^+ , 9.31), 209 (100); HRMS calculated for $[C_{20}H_{25}BO_3]^+$: 290.1307 found: 290.1311. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (hexanes : 2-propanol = 95:5, 0.5 mL/min, 220 nm); minor enantiomer t_r = 9.5 min, major enantiomer t_r = 8.1 min. $[\alpha]_D^{20}$ = 76.6 (c = 0.4, acetone).

6. X-ray structure of 4d.







7. 1H , ^{19}F , ^{13}C NMR and HPLC Spectra









Integration Results							
No.	Peak Name	Retention Time min	Area mAU*min	Height mAU	Relative Area %	Relative Height %	Amount
1		9.820	54.440	315.543	50.01	51.70	n.a.
2		10.357	54.412	294.762	49.99	48.30	n.a.
Total:			108.852	610.305	100.00	100.00	

















Integration Results



No.	Peak Name	Retention Time min	Area mAU*min	Height mAU	Relative Area %	Relative Height %	Amount
1		9.100	40.288	252.554	50.25	58.02	n.a.
2		12.810	39.890	182.713	49.75	41.98	n.a.
Total:			80.178	435.267	100.00	100.00	





















































































<Chromatogram>

mAU




<Peak Table>

PDA Ch2 220nm

Peak#	Ret. Time	Area	Area%	Height	Height%
1	14.856	5208712	50.096	289354	57.252
2	19.274	5188806	49.904	216049	42.748
Total		10397517	100.000	505403	100.000

<Chromatogram>



mAU







<Peak Table>



PDA Ch1 220nm



Peak#	Ret. Time	Area	Area%	Height	Height%
1	14.878	306521	4.815	17077	6.459
2	19.291	6060051	95.185	247306	93.541
Total		6366573	100.000	264383	100.000




































































































VWD1A, Wavelength=220 nm

Ret. Time [min]	Area	Height	Height%	Area%
16.645	2557.69	38.15	59.46	49.51
22.094	2608.13	26.01	40.54	50.49
Total.	5165.81	64.16	100.00	100.00








VWD1A, Wavelength=220 nm



Ret. Time [min]	Area	Height	Height%	Area%
16.539	1271.31	19.56	13.39	8.97
21.979	12897.34	126.53	86.61	91.03
Total.	14168.65	146.09	100.00	100.00





---124.34










Integration Results							
No.	Peak Name	Retention Time min	Area mAU*min	Height mAU	Relative Area %	Relative Height %	Amount
1		10.233	29.855	174.430	49.96	52.07	n.a.
2		10.930	29.904	160.567	50.04	47.93	n.a.
Total:			59.760	334.997	100.00	100.00	




156.86
 137.27
 129.44
 127.99
 123.14
 108.93
 84.21
 83.10
 77.32
 77.00
 76.68
 43.14
 27.83
 24.76
 24.67
 20.82



4c











7.46
7.45
7.44
7.43
7.32
7.31
7.30
7.28
7.23
6.78
6.72


4.40
4.38
4.23
4.21

1.33
1.28
1.24
1.20
1.16
1.09
1.08










<Chromatogram>

mAU




<Peak Table>

PDA Ch2 220nm

Peak#	Ret. Time	Area	Area%	Height	Height%
1	9.524	3591441	49.845	272658	48.687
2	10.999	3613770	50.155	287364	51.313
Total		7205211	100.000	560023	100.000

<Chromatogram>


mAU







<Peak Table>



PDA Ch2 220nm



Peak#	Ret. Time	Area	Area%	Height	Height%
1	9.511	5360592	96.165	385696	95.688
2	10.950	213761	3.835	17382	4.312
Total		5574353	100.000	403078	100.000














-155.43
 -138.29
 -133.58
 -130.46
 -129.13
 -127.30
 -127.13
 -126.78
 -126.57
 -112.60
 -107.37
 -106.17

-83.88
 -83.11
 -77.32
 -77.00
 -76.66

-44.21
 -27.64
 -24.59




4h




VWD1A, Wavelength=250 nm


Ret. Time [min]	Area	Height	Height%	Area%
16.728	407.03	19.09	55.00	50.67
20.142	396.21	15.62	45.00	49.33
Total.	803.24	34.71	100.00	100.00



VWDIA, Wavelength=250 nm


Ret. Time [min]	Area	Height	Height%	Area%
16.686	3669.47	163.65	91.38	90.17
20.123	400.01	15.43	8.62	9.83
Total.	4069.48	179.08	100.00	100.00





<Chromatogram>

mAU




<Peak Table>

PDA Ch1 254nm

Peak#	Ret. Time	Area	Area%	Height	Height%
1	18.184	43596	49.008	1868	53.413
2	19.779	45362	50.992	1629	46.587
Total		88958	100.000	3497	100.000

<Chromatogram>


mAU




<Peak Table>

PDA Ch1 254nm


Peak#	Ret. Time	Area	Area%	Height	Height%
1	18.212	101465	7.464	4314	9.405
2	19.363	1257906	92.536	41560	90.595
Total		1359371	100.000	45874	100.000





<Chromatogram>

mAU




<Peak Table>

PDA Ch1 254nm

Peak#	Ret. Time	Area	Area%	Height	Height%
1	12.358	474361	49.449	26692	51.991
2	13.874	484928	50.551	24648	48.009
Total		959289	100.000	51340	100.000

<Chromatogram>


mAU





<Peak Table>

PDA Ch1 254nm


Peak#	Ret. Time	Area	Area%	Height	Height%
1	12.349	41346	5.577	2420	6.369
2	13.871	700075	94.423	35572	93.631
Total		741421	100.000	37992	100.000






VWD1A, Wavelength=220 nm



Ret. Time [min]	Area	Height	Height%	Area%
28.752	5373.05	69.33	47.69	50.75
31.951	5213.97	76.04	52.31	49.25
Total.	10587.02	145.38	100.00	100.00





VWD1A, Wavelength=220 nm



Ret. Time [min]	Area	Height	Height%	Area%
29.916	9252.23	153.44	77.21	76.49
33.558	2844.20	45.30	22.79	23.51
Total.	12096.42	198.74	100.00	100.00







Integration Results							
No.	Peak Name	Retention Time min	Area mAU*min	Height mAU	Relative Area %	Relative Height %	Amount
1		16.493	78.578	123.332	50.22	51.17	n.a.
2		17.883	77.904	117.714	49.78	48.83	n.a.
Total:			156.482	241.046	100.00	100.00	








<Chromatogram>

mAU




<Peak Table>

PDA Ch2 220nm

Peak#	Ret. Time	Area	Area%	Height	Height%
1	10.700	7654150	50.047	661981	51.596
2	11.554	7639885	49.953	621037	48.404
Total		15294036	100.000	1283018	100.000

<Chromatogram>



mAU



<Peak Table>


PDA Ch2 220nm

Peak#	Ret. Time	Area	Area%	Height	Height%
1	10.614	23993482	95.883	1939038	95.804
2	11.470	1030228	4.117	84917	4.196
Total		25023710	100.000	2023954	100.000



<Chromatogram>

mAU




<Peak Table>

PDA Ch2 220nm

Peak#	Ret. Time	Area	Area%	Height	Height%
1	8.140	815402	49.977	83032	54.629
2	9.553	816138	50.023	68961	45.371
Total		1631540	100.000	151994	100.000

<Chromatogram>

mAU



<Peak Table>

PDA Ch2 220nm

Peak#	Ret. Time	Area	Area%	Height	Height%
1	8.131	18254957	97.318	1942884	97.611
2	9.546	503172	2.682	47555	2.389
Total		18758129	100.000	1990439	100.000

8. References

1. L. Wang, M. Chen, P. Zhang, W. Li and J. Zhang, *J. Am. Chem. Soc.*, 2018, **140**, 3467-3473.
2. W. Zhou, P. Chen, M. Tao, X. Su, Q. Zhao and J. Zhang, *Chem. Commun.*, 2016, **52**, 7612-7615.
3. H. Hu, Y. Wang, D. Qian, Z. Zhang, L. Liu and J. Zhang, *Org. Chem. Front.*, 2016, **3**, 759-763.
4. Z. Zhang, P. Chen, W. Li, Y. Niu, X. Zhao and J. Zhang, *Angew. Chem., Int. Ed.*, 2014, **53**, 4350-4354.
5. Z. Zhang, B. Xu, Y. Qian, L. Wu, Y. Wu, L. Zhou, Y. Liu and J. Zhang, *Angew. Chem., Int. Ed.*, 2018, **57**, 10373-10377.
6. Z. Zhang, B. Xu, L. Wu, Y. Wu, Y. Qian, L. Zhou, Y. Liu and J. Zhang, *Angew. Chem., Int. Ed.*, 2019, **58**, 14653-14659.
7. O. M. Saavedra, D. Karila, D. Brossard, A. Rojas, D. Dupuis, A. Gohier, C. Mannoury la Cour, M. J. Millan, J. Ortuno and S. Hanessian, *Bioorg. Med. Chem.*, 2017, **25**, 38-52.
8. Y. Feng, S. Yang, S. Zhao, D. Zhang, X. Li, H. Liu, Y. Dong, F. Sun. *Org. Lett.*, 2020, **22**, 6734-6738.
9. A. Whyte, K. I. Burton, J. Zhang and M. Lautens, *Angew. Chem., Int. Ed.*, 2018, **57**, 13927-13930.
10. D. D. Vachhani, H. H. Butani, N. Sharma, U. C. Bhoya, A. K. Shah and E. V. Van der Eycken, *Chem. Commun.*, 2015, **51**, 14862-14865.
11. W. Wang, C. Ding and G. Yin, *Nat. Catal.*, 2020, **3**, 951-958.